Effect of Number of Treatment Cycles of Adjuvant Chemotherapy on Clinical Outcomes


Effect of Number of Treatment Cycles of Adjuvant Chemotherapy on Clinical Outcomes
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)
Shulman LN et al. Four vs 6 cycles of doxorubicin and cyclophosphamide (AC) or paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101 — A 2x2 factorial phase III trial: First results comparing 4 vs 6 cycles of therapy. San Antonio Breast Cancer Symposium 2010;Abstract S6-3.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.